Abstract
Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5-1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a considerable proportion of patients do not benefit from these, and the need for alternative treatment strategies is clear. This review explores the potential for a therapy targeting the adaptive immune system by modulating co-stimulation of T cells with a CTLA4-Ig fusion protein (abatacept).
MeSH terms
-
Abatacept
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents / pharmacology
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / immunology
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / immunology
-
B7-1 Antigen / immunology
-
CD28 Antigens / immunology
-
CD4-Positive T-Lymphocytes / immunology
-
Humans
-
Immunoconjugates / therapeutic use
-
Lymphocyte Activation / drug effects*
-
Mice
-
Rituximab
-
T-Lymphocyte Subsets / drug effects
-
T-Lymphocyte Subsets / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
B7-1 Antigen
-
CD28 Antigens
-
Immunoconjugates
-
Rituximab
-
Abatacept